Peking Union Medical College Hospital Launches Clinical Trial Recruitment for 'Beinao No.1' Implantable Brain-Computer Interface System
NEUCYBER
Brain-Computer Interface System R&D Service Provider
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Dear Patients and Family Members:
Our hospital's Department of Neurosurgery is currently conducting a clinical trial:A Prospective, Multicenter, Single-Arm Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Flexible Intracortical Brain-Computer Interface System for Motor Function Restoration in Patients with Quadriplegia Due to Spinal Cord Injury(Protocol Number: XZDNMGCP001), the Principal Investigator isZhao Yuanli. This study has been approved by the Medical Ethics Committee of our hospital (Approval No.: KS20261102), and we are now publicly recruiting participants (individuals with quadriplegia resulting from cervical spinal cord injury).
The investigational medical device in this study is “Implantable Flexible Intracortical Brain-Computer Interface System"Also known as (“Beijing Brain One” Intelligent Brain-Computer Interface System), provided by NEUCYBER, classified as a Class III medical device. This study will last approximately 26 weeks (6 months), during which there will be five on-site follow-up visits. For each visit, patients are required to come to the hospital for various examinations conducted by physicians to assess their health status.
Eligibility Criteria:
The study physician will provide you with detailed information regarding this clinical trial, and both the patient and the physician must voluntarily sign the informed consent form prior to screening. The main inclusion criteria are as follows:
(1)）
Age: 18–65 years, inclusive; no gender restriction;
(2)
Cervical spinal cord injury resulting in quadriplegia for more than 12 months, with no further improvement in upper limb motor function after inpatient rehabilitation therapy;
(3)
In a seated position without assistance, the patient can manually touch their mouth but cannot grasp a water cup;
(4)
Normal bilateral visual acuity or corrected visual acuity, normal hearing, and normal language comprehension;
(5)
Voluntarily participate in the clinical trial with good compliance, and be able to cooperate in completing the relevant examinations, brain-computer interface training, and follow-up procedures required by the study.
Registration Method:
If you are interested in participating in this study or would like to learn more, please contact us.
Contact Person and Contact Information:
Dr. Chang 13120011516
Recruitment Period：
Planned: March 2026 – August 2026 (until positions are filled)
Principal Investigator Profile：
Professor Zhao Yuanli
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Professor, Chief Physician, Doctoral Supervisor, Director of the Department of Neurosurgery at Peking Union Medical College Hospital
Primarily engaged in clinical and basic research on complex and refractory cerebrovascular diseases and brain tumors.
Presided over multiple national and provincial/ministerial-level research projects, including the National Natural Science Foundation of China, the National Key R&D Program, the National Key Technologies R&D Program, the National Science and Technology Support Program, the Clinical Research Special Project (Major Key Problems) for Central High-Level Hospitals at Peking Union Medical College Hospital, and the Beijing Natural Science Foundation.
Serves as a Standing Committee Member of the Neurosurgery Branch of the Chinese Medical Association; selected as a National Candidate of the “Hundred, Thousand, and Ten Thousand Talents Project” and recognized as a National Mid-career and Young Expert with Outstanding Contributions. Has published over 200 SCI-indexed papers, with an H-index of 39 and more than 6,300 citations; served as Editor-in-Chief and authored monographs such as Essentials of Neurosurgery.
Scan the QR code to proceedProfessor Zhao YuanliAcademic Homepage
View More Exciting Content
Share
Add to Favorites
Like
Click "Like"